Galmed Pharmaceuticals
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 8
- Market Cap
- $1.8M
- Website
- http://galmedpharma.com
- Introduction
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese ...
Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Galmed Pharmaceuticals Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT06502561
- Locations
- 🇧🇬
Diagnostic & Consultative Centre 'Ascendent' Ltd., Sofia, Bulgaria
An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Galmed Pharmaceuticals Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT05874336
- Locations
- 🇬🇧
Quotient Sciences, Mere Way, Ruddington Fields, Ruddington, Nottingham, NG11 6JS, UK., Nottingham, United Kingdom
A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Galmed Pharmaceuticals Ltd
- Target Recruit Count
- 55
- Registration Number
- NCT05857215
- Locations
- 🇬🇧
Quotient Sciences, Mere Way, Ruddington, Nottingham, NG11 6JS, UK, Nottingham, United Kingdom
Comparison of Aramchol Concentrations With Once or Twice Daily Dosing
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Galmed Pharmaceuticals Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT03774173
- Locations
- 🇬🇧
Hammersmith Medicines Research (HMR), London, United Kingdom
Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- Galmed Pharmaceuticals Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT03760848
- Locations
- 🇬🇧
Hammersmith Medicines Research (HMR), London, United Kingdom
Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered Under Fed Conditions in Healthy Chinese Volunteers
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Galmed Pharmaceuticals Ltd
- Target Recruit Count
- 64
- Registration Number
- NCT02803996
- Locations
- 🇺🇸
WCCT Global, LLC., Cypress, California, United States
Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2015-02-27
- Lead Sponsor
- Galmed Pharmaceuticals Ltd
- Target Recruit Count
- 66
- Registration Number
- NCT02374437
Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- Galmed Pharmaceuticals Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT02325492
- Locations
- 🇮🇱
Assuta Medical Center, Tel Aviv, Israel